Dr. Keith Flaherty, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Johns Hopkins School Of Medicine

  Medical School, 1997

• PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hicells and anti-PD-1 resistance, 2019-07-29

• A melanocyte lineage program confers resistance to MAP kinase pathway inhibition, 2013-11-03

• Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer, 2014-11-13

• A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh/AXLlowmelanoma, 2018-10-19

• Plasma KIM-1 is associated with recurrence risk after nephrectomy for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805), 2021-04-08

• Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for TargetingDe NovoResistance Using BH3 Mimetics, 2014-07-01

• Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma, 2018-03-21

• MAPK Pathway Inhibitors Sensitize BRAF Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB, 2016-08-11

• Targeting wild-typeTP53using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study, 2022-05-30

• Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma, 2022-08-29

• sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance, 2016-04-04

• BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance, 2011-11-17

• Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma, 2016-08-08

• A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAFmutation, 2021-01-06

• Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFN? pathways, 2019-11-27

• HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+T-cell infiltration into tumors, 2022-07-14

• Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas, 2022-05-13

• Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM, 2019-08-16

• Evolution of Delayed Resistance to Immunotherapy in a Melanoma Responder, 2021-05-03

• Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells, 2014-12-29

• The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: Where we have been, are, and will be, 2013-10-01

• Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma, 2015-07-14

• Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation, 2015-05-28

• Parallel in-vivo assessment of drug phenotypes at various time points during systemic BRAF inhibition reveals tumor adaptation and altered treatment vulnerabilities, 2016-04-18

• MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition, 2013-11-21

• A fatty acid oxidation-dependent metabolic shift regulates the adaptation ofBRAF-mutated melanoma to MAPK inhibitors, 2019-08-02

• Biology of Advanced Uveal Melanoma and Next Steps for Clinical Therapeutics, 2014-09-01

• Mechanisms of resistance to immune checkpoint inhibitors, 2018-01-02

• Myc-driven glycolysis is a therapeutic target in glioblastoma, 2016-04-13

• An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition, 2017-06-05

• A comprehensive patient-derived xenograft collection representing the heterogeneity of melanoma, 2017-11-14

• Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel, 2013-08-06

• The State of Melanoma: Emergent Challenges and Opportunities, 2021-01-07

• A Randomized Study of Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer in the ECOG-ACRIN Cancer Research Group (EAQ152), 2021-12-10

• Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: results from NCI-MATCH (EAY131), 2020-01-10

• The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling, 2013-03-18

• Long-term outcome inBRAFV600Emelanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression, 2015-05-13

• BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma, 2013-01-10

• MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603, 2015-06-04

• The immune-microenvironment confers resistance to MAP kinase pathway inhibitors through macrophage-derived TNFa, 2014-08-01

• COT/MAP3K8drives resistance to RAF inhibition through MAP kinase pathway reactivation, 2010-11-24

• Reversal of pre-existing NGFR-driven tumor and immune therapy resistance, 2020-08-07

• Ligand independent EphA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype, 2014-12-26

• Targeting Extracellular Matrix Remodeling restores BRAF Inhibitor Sensitivity in BRAFi Resistant Melanoma, 2020-08-20

• BRAF inhibitors amplify the pro-apoptotic activity of MEK inhibitors by inducing ER stress in NRAS-mutant melanoma, 2017-07-19

• Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials, 2014-01-31

• Tumor microvessel density as a prognostic marker in high-risk renal cell carcinoma patients treated on ECOG-ACRIN E2805, 2017-10-24

• A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade, 2018-11-01

• Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance, 2023-02-07

• Differential Outcomes in Codon 12/13 and Codon 61NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients withNRAS-Mutated Tumors, 2021-02-26

• Mutation-driven drug development in melanoma, 2011-05-16

• Rethinking cancer clinical trial conduct induced by COVID-19: An academic center, industry, government and regulatory agency perspective, 2021-07-21

• Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual, 2017-10-13

• Isolation and Molecular Characterization of Circulating Melanoma Cells, 2014-04-18

• Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy, 2015-12-01

• Local Recurrence Following Resection of Intermediate-High Risk Non-Metastatic Renal Cell Carcinoma: An Anatomic Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial, 2019-10-09

• Dabrafenib plus trametinib in patients withBRAFV600-mutant melanoma brain metastases (COMBI-MB): a multi-cohort, open-label, phase 2 trial, 2017-06-04

• Changes in Aged Fibroblast Lipid Metabolism Induce Age-dependent Melanoma Cell Resistance to Targeted Therapy Via the Fatty Acid Transporter FATP2, 2020-06-04

• PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation, 2014-03-31

• Resistance to checkpoint blockade therapy through inactivation of antigen presentation, 2017-10-26

• A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status, 2017-07-18

• Defining T cell states associated with response to checkpoint immunotherapy in melanoma, 2018-11-01

• EGFR-mediated re-activation of MAPK signaling contributes to insensitivity ofBRAFmutant colorectal cancers to RAF inhibition with vemurafenib, 2012-01-16

• Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center and University Hospital of Lausanne experience, 2013-08-02

• Neural crest-like stem cell transcriptome analysis identifies LPAR1 in melanoma progression and therapy resistance., 2021-08-30

• Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure, 2017-06-12

• Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment, 2015-10-13

• MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway, 2017-04-19

• MITF Modulates Therapeutic Resistance through EGFR Signaling, 2015-03-19

• Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq, 2016-04-08

• Melanoma and immunotherapy bridge 2015 Naples, Italy. 1-5 December 2015, 2016-07-25

• Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion, 2012-07-26

• Correlation of somatic mutations and clinical outcome in melanoma patients treated with carboplatin, paclitaxel, and sorafenib, 2014-04-08

• Targeting TBK1 to overcome resistance to cancer immunotherapy, 2023-01-12

• TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition inBRAF-Mutant Melanoma, 2013-07-31

• Clinical utility of a blood-based BRAF V600E mutation assay in melanoma, 2014-10-15

• Copy number changes are associated with response to treatment with carboplatin, paclitaxel and sorafenib in melanoma, 2015-08-25

• STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming, 2022-04-06

• Fibronectin induction abrogates the BRAF inhibitor response ofBRAFV600E/PTEN-null melanoma cells, 2015-06-15

• Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel with Necuparanib or Placebo in Untreated Metastatic Pancreas Ductal Adenocarcinoma, 2020-04-28

• Ex VivoProfiling of PD-1 Blockade Using Organotypic Tumor Spheroids, 2017-11-03

• An Open-label, Dose-Escalation Phase 1 Study of anti-TYRP1 monoclonal antibody IMC-20D7S for patients with relapsed or refractory melanoma, 2016-10-19

• The association of BMI and outcomes in metastatic melanoma: A retrospective, multicohort analysis of patients treated with targeted therapy, immunotherapy, or chemotherapy, 2018-02-12

• Moving treatments earlier to move further forward, 2017-11-28

• MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability inBRAF,NRAS, andNF1mutant melanomas, 2019-02-01

• Multiple gastrointestinal polyps in patients treated with BRAF inhibitors, 2015-07-22

• Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors, 2017-03-09

• A Melanoma Molecular Disease Model, 2011-03-30

• Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma, 2021-03-09

• Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH), 2020-10-13

• Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial, 2019-08-12

• Impact of initial treatment and prognostic factors on postprogression survival inBRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials, 2020-08-03

• Safety and efficacy of vemurafenib inBRAFV600EandBRAFV600Kmutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, 2014-02-07

• SARS-CoV-2 viral load is associated with increased disease severity and mortality, 2020-10-30

• National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH), 2023-04-14

• Adjuvant therapy in patients with sarcomatoid RCC: Post hoc analysis from ECOG-ACRIN E2805, 2021-09-23

• The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies, 2015-02-09

• Spartalizumab or placebo in combination with dabrafenib and trametinib in patients withBRAFV600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i), 2022-06-21

• BRAF inhibition generates a host/tumor niche that mediates therapeutic escape, 2015-08-24

• Feasibility of ultra-high-throughput functional screening of melanoma biopsies for discovery of novel cancer drug combinations, 2017-04-26

• Overexpression of Mcl-1 confers resistance to BRAFV600Einhibitors alone and in combination with MEK1/2 inhibitors in melanoma, 2015-10-14

• ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma, 2018-12-18

• Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results, 2014-05-06

• BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Anti-tumor Activity of Adoptive Immunotherapy in Mice, 2012-11-30

• Genetic and genomic characterization of 462 melanoma patient-derived xenografts, tumor biopsies and cell lines, 2017-11-14

• Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine, 2017-09-15

• Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth, 2015-09-10

• Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade, 2014-04-29

• Precision medicine for cancer with next-generation functional diagnostics, 2015-11-05

• EphA2 is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma, 2014-12-26

• Pathways and therapeutic targets in melanoma, 2014-04-08

• Systematic identification of signaling pathways with potential to confer anticancer drug resistance, 2014-12-23

• Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma, 2021-10-15

• Two Phase II Trials of the Novel Akt Inhibitor Perifosine in Patients with Advanced Renal Cell Carcinoma Following Progression on VEGF-Targeted Therapy, 2012-06-06

• Discovery of targets for immune-metabolic antitumor drugs identifies Estrogen Related Receptor Alpha, 2023-03-01

• A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors, 2014-04-25

• PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors inBRAF-mutant Melanomas, 2017-09-27

• The State of Melanoma: Challenges and Opportunities, 2016-04-17

• Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy, 2016-03-14

• Melanoma therapeutic strategies that select against resistance by exploiting MYC-driven evolutionary convergence, 2017-12-05

• Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors Through Autocrine FGFR Pathway Activation, 2019-09-12

• RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), 2011-11-23

• Reduced Proteolytic Shedding of Receptor Tyrosine Kinases is a Post-Translational Mechanism of Kinase Inhibitor Resistance, 2016-03-16

• Melanoma: New Insights and New Therapies, 2012-01-05

• Targeting the RAS pathway in melanoma, 2011-09-30

• New challenges in endpoints for drug development in advanced melanoma, 2011-12-05

• Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR, 2015-06-01

• Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma, 2014-04-21

• Epitope spreading toward wild type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses, 2021-02-17

• Oncogenic RAS regulates long non-coding RNAOrilnc1in human cancer, 2017-05-04

• Extreme vulnerability ofIDH1mutant cancers to NAD+ depletion, 2015-12-14